Peptide Based Gastrointestinal Disorders Therapeutics: Market Anticipated for Progressive CAGR Growth during 2017-2022

Medical research institutes, as well as leading companies in the pharmaceutical industry, are ramping up their efforts toward development of profound therapeutic drugs for treating gastrointestinal disorders. This Fact.MR report analyzes the expansion of global peptide based gastrointestinal disorders therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022. The scope of Fact.MR’s report is to analyze the global peptide based gastrointestinal disorders therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Drug manufacturers, research institutes, and raw material suppliers in the global peptide based gastrointestinal disorders therapeutics market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based gastrointestinal disorders therapeutics. The report commences with a brief information of the global peptide based gastrointestinal disorders therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based gastrointestinal disorders therapeutics market.   

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=190

According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.

Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years. Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well. Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders. Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs.

Peptide is a biologically, naturally or artificially constituted form of amino acid monomers. Peptides can be utilized for treating various gastrointestinal disorders that mostly effect parts of the digestive system such as the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum. Peptides are considered as an effective therapeutic agent for treating gastrointestinal diseases. Owing to their impressive preclinical results, an array of new peptide based gastrointestinal disorder therapeutics are expected to enter the market soon.

Browse Full Report with TOC- https://www.factmr.com/report/190/peptide-based-gastrointestinal-disorders-therapeutics-market

North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market

In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region.  During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.

On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.

Competition Tracking

Shire plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan plc, Accredo Health Group, Inc., are the key market players profiled in the Fact.MR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio. This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.

Check Discount on this Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=190

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.